Shenzhen Hybio Pharmaceutical: difference between revisions
Diff·revision 14 → 15·15:16, 10 Nov 2025
Difference between revision 14 and revision 15 of Shenzhen Hybio Pharmaceutical. 3 lines changed; the page grew by 691 bytes.
| Revision 14 — 10:43, 2 Nov 2025 Chromatokid (talk) add the note that self-published material is usable only for what it states about itself 9,293 bytes ±0 | Revision 15 — 15:16, 10 Nov 2025 CategoryBot (talk) bot: update parent category chain 9,984 bytes +691 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Notability, and what a long registry record does not establish}} | |
| 21 | 22 | ||
| 22 | '''Shenzhen Hybio Pharmaceutical Co., Ltd.''' (trading as '''HYB'''; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} | 23 | '''Shenzhen Hybio Pharmaceutical Co., Ltd.''' (trading as '''HYB'''; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 56 | == Independent testing record == | 57 | == Independent testing record == |
| 57 | Reports on HYB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported [[Area percent purity|area percent]] figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point.{{r|reports}} | 58 | Reports on HYB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported [[Area percent purity|area percent]] figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point.{{r|reports}} |
| + | 59 | ||
| + | 60 | Agreement of that kind is a weaker finding than it appears. It establishes that two measurements of one sample agreed; it establishes nothing about the lot the sample was drawn from, because none of these reports arose from a [[Blind sampling|blind sampling]] procedure with a documented [[Chain of custody|chain of custody]].{{r|reports}} The more informative observation is the documentary one recorded above: where water and [[Peptide content|peptide content]] accompany the purity figure, a second laboratory can reproduce the determination rather than merely repeat it.{{r|usp1503}} | |
| 58 | 61 | ||
| 59 | == References == | 62 | == References == |